HSBC Holdings’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $773K | Sell |
2,455
-1,000
| -29% | -$236K | ﹤0.01% | 2074 |
|
|
2026
Q1 | $690K | Buy |
+3,455
| New | +$684K | ﹤0.01% | 2057 |
|
|
2025
Q1 | – | Sell |
-3,764
| Closed | -$398K | – | 3175 |
|
|
2024
Q4 | $398K | Buy |
3,764
+605
| +19% | +$68.4K | ﹤0.01% | 2315 |
|
|
2024
Q3 | $315K | Sell |
3,159
-1,482
| -32% | -$149K | ﹤0.01% | 2309 |
|
|
2024
Q2 | $388K | Sell |
4,641
-603
| -11% | -$48K | ﹤0.01% | 2124 |
|
|
2024
Q1 | $383K | Buy |
+5,244
| New | +$387K | ﹤0.01% | 2254 |
|
|
2023
Q3 | – | Sell |
-3,949
| Closed | -$286K | – | 2776 |
|
|
2023
Q2 | $286K | Sell |
3,949
-44
| -1% | -$3.3K | ﹤0.01% | 2171 |
|
|
2023
Q1 | $294K | Buy |
+3,993
| New | +$284K | ﹤0.01% | 2235 |
|
|
2022
Q4 | – | Sell |
-4,059
| Closed | -$226K | – | 3119 |
|
|
2022
Q3 | $226K | Sell |
4,059
-1,763
| -30% | -$104K | ﹤0.01% | 2572 |
|
|
2022
Q2 | $324K | Sell |
5,822
-645
| -10% | -$36.6K | ﹤0.01% | 2590 |
|
|
2022
Q1 | $461K | Buy |
6,467
+4,361
| +207% | +$316K | ﹤0.01% | 2476 |
|
|
2021
Q4 | $205K | Buy |
+2,106
| New | +$195K | ﹤0.01% | 3024 |
|
|
2020
Q4 | – | Sell |
-7,909
| Closed | -$478K | – | 3094 |
|
|
2020
Q3 | $478K | Sell |
7,909
-9,266
| -54% | -$632K | ﹤0.01% | 1975 |
|
|
2020
Q2 | $1.2M | Buy |
17,175
+6,073
| +55% | +$385K | ﹤0.01% | 1365 |
|
|
2020
Q1 | $498K | Buy |
11,102
+7,989
| +257% | +$453K | ﹤0.01% | 1784 |
|
|
2019
Q4 | $205K | Sell |
3,113
-4,833
| -61% | -$323K | ﹤0.01% | 2793 |
|
|
2019
Q3 | $493K | Sell |
7,946
-35,002
| -81% | -$2.2M | ﹤0.01% | 2348 |
|
|
2019
Q2 | $3.06M | Sell |
42,948
-57,342
| -57% | -$4.22M | 0.01% | 1352 |
|
|
2019
Q1 | $7.87M | Buy |
100,290
+35,058
| +54% | +$2.66M | 0.01% | 925 |
|
|
2018
Q4 | $5.52M | Buy |
65,232
+49,058
| +303% | +$5.23M | 0.01% | 1065 |
|
|
2018
Q3 | $2.77M | Buy |
16,174
+2,747
| +20% | +$414K | ﹤0.01% | 1354 |
|
|
2018
Q2 | $1.74M | Sell |
13,427
-17,795
| -57% | -$1.99M | ﹤0.01% | 1552 |
|
|
2018
Q1 | $3.22M | Sell |
31,222
-23,931
| -43% | -$2.37M | ﹤0.01% | 1270 |
|
|
2017
Q4 | $4.71M | Buy |
55,153
+574
| +1% | +$49.8K | 0.01% | 863 |
|
|
2017
Q3 | $4.63M | Sell |
54,579
-14,901
| -21% | -$1.18M | 0.01% | 1062 |
|
|
2017
Q2 | $5.26M | Sell |
69,480
-5,212
| -7% | -$365K | 0.01% | 963 |
|
|
2017
Q1 | $4.93M | Sell |
74,692
-535
| -0.7% | -$35.2K | 0.01% | 933 |
|
|
2016
Q4 | $4.77M | Buy |
75,227
+17,048
| +29% | +$1.08M | 0.01% | 939 |
|
|
2016
Q3 | $3.7M | Buy |
58,179
+14,715
| +34% | +$1.08M | 0.01% | 1004 |
|
|
2016
Q2 | $3.23M | Buy |
43,464
+962
| +2% | +$71.4K | 0.01% | 1058 |
|
|
2016
Q1 | $2.84M | Buy |
42,502
+4,426
| +12% | +$269K | 0.01% | 1061 |
|
|
2015
Q4 | $2.58M | Sell |
38,076
-7,190
| -16% | -$444K | 0.01% | 1186 |
|
|
2015
Q3 | $2.42M | Buy |
45,266
+541
| +1% | +$32.8K | 0.01% | 1014 |
|
|
2015
Q2 | $2.81M | Sell |
44,725
-2,445
| -5% | -$133K | 0.01% | 987 |
|
|
2015
Q1 | $2.27M | Sell |
47,170
-276
| -0.6% | -$10.6K | ﹤0.01% | 1144 |
|
|
2014
Q4 | $1.57M | Buy |
47,446
+5,026
| +12% | +$163K | ﹤0.01% | 1221 |
|
|
2014
Q3 | $1.24M | Buy |
+42,420
| New | +$1.41M | ﹤0.01% | 1287 |
|
Other funds holding LGND
JT
CAM
HSBC Holdings's LGND Position: Q2 2026 in Review
HSBC Holdings reduced its Ligand Pharmaceuticals (LGND) stake by 29% in Q2 2026, selling an estimated $236K and leaving 2,455 shares worth $773K. The position accounts for ﹤0.01% of the portfolio, ranked #2074.
HSBC Holdings first reported a position in LGND in Q3 2014 and has held it in 37 quarters since. The position peaked at $7.87M in Q1 2019. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- HSBC Holdings held 2,455 shares of Ligand Pharmaceuticals worth $773K as of Q2 2026.
- HSBC Holdings sold 1,000 Ligand Pharmaceuticals shares in Q2 2026, an estimated $236K.
- Ligand Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2074 holding.
- HSBC Holdings first reported a position in Ligand Pharmaceuticals in Q3 2014 and has held it in 37 quarters since.
- HSBC Holdings's Ligand Pharmaceuticals position peaked at $7.87M in Q1 2019.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.